The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors

Histone deacetylases (HDACs) are epigenetic drug targets that have gained major scientific attention. Inhibition of these important regulatory enzymes is used to treat cancer, and has the potential to treat a host of other diseases. However, currently marketed HDAC inhibitors lack selectivity for th...

Full description

Bibliographic Details
Main Authors: Fangyuan Cao, Martijn R. H. Zwinderman, Frank J. Dekker
Format: Article
Language:English
Published: MDPI AG 2018-03-01
Series:Molecules
Subjects:
Online Access:http://www.mdpi.com/1420-3049/23/3/551